pki-179
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT00997360)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- PI3-kinase p110-alpha subunitINHIBITOR
PIK3CA inhibitor
ATP-competitive PI3K/mTOR inhibitor
- Serine/threonine-protein kinase mTORINHIBITOR
MTOR inhibitor
ATP-competitive PI3K/mTOR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1- Mol. weight
- 488.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1258517 ↗
Also known as
- 1-(4-(4-(3-oxa-8-azabicyclo(3.2.1)octan-8-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea
- pki-179
- pki-179
- pki-179
- pki-179
- pki-179
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00997360 | Phase 1 | Feb 1, 2010 | Pfizer, Wyeth |
Showing 1 of 1 trials
Page 1 / 1